ALRTF ALR Technologies SG Ltd. Annual reports only
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1930419
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY978.8%
TTM net income YoY29.6%
TTM EPS YoY50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin13.5%
Operating margin—
Net margin-29,270.5%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-2,807.4%
ROIC (approx.)—
Asset turnover0.10x
Leverage & solvency
Liabilities / assets20,664.8%
Debt / equity—
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.22x
Accruals ratio-2,198.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $25,536 | $2,367 | $7,468 |
| Cost of revenue | — | — | $22,096 | $1,176 | $2,523 |
| Gross profit | — | — | $3,440 | $1,191 | $4,945 |
| R&D expense | $793,327 | $883,866 | $1.40M | $482,141 | $498,996 |
| SG&A expense | $1.47M | $2.02M | $2.60M | $2.87M | $1.57M |
| Operating income | — | — | — | $4.27M | $2.95M |
| Interest expense | -$19.74M | -$12.42M | -$2.52M | -$6.35M | $5.47M |
| Pretax income | -$2.26M | -$15.88M | -$7.47M | — | — |
| Net income | -$22.06M | -$15.88M | -$7.47M | -$10.62M | -$8.44M |
| EPS (basic) | — | -0.03 | -0.01 | -0.02 | — |
| EPS (diluted) | -0.04 | -0.03 | -0.01 | -0.02 | — |
| Weighted avg. shares (diluted) | 606.99M | 598.92M | 581.02M | 548.08M | — |
| Banking | |||||
| Net interest income | $17.29M | $9.82M | — | $4.00M | $3.43M |
| Balance sheet | |||||
| Cash & equivalents | $20,305 | $40,657 | $59,082 | $148,628 | $115,922 |
| Receivables | — | — | $41,100 | — | — |
| Inventory | $10,843 | $10,863 | $11,000 | — | — |
| Total assets | $47,374 | $79,472 | $155,198 | $377,289 | $193,217 |
| Current liabilities | — | — | $32.07M | $27.09M | $24.51M |
| Total liabilities | $39.91M | $36.30M | $32.07M | $28.93M | $24.51M |
| Shareholders' equity | -$39.86M | -$36.22M | -$31.92M | -$28.55M | -$24.31M |
| Shares outstanding | — | — | — | 551.97M | 542.72M |
| Cash flow statement | |||||
| Operating cash flow | -$1.87M | -$1.54M | -$1.62M | -$2.57M | -$2.22M |
| Financing cash flow | $1.85M | $1.52M | $1.54M | $2.51M | $2.29M |
| Stock-based compensation | $17.29M | $9.82M | — | $4.00M | $3.43M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.